Hy2Care BV develops a novel technology platform consisting of injectable hydrogels to fight osteoarthritis
Hy2Care BV is a business start-up of the University of Twente, the Netherlands. It is Hy2Care’s ambition to introduce into the market the first cure for Osteoarthritis, the injectable hydrogel.Osteoarthritis is the 4th leading cause of mobility associated disability and affects more than 100 million patients in the Western world, who are all in need for an effective treatment.It is the aim of Hy2Care to change the future for patients suffering from osteoarthritis.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 6, 2022 | Grant | €6M | 1 | European Innovation Council | — | Detail |
May 1, 2019 | Series A | €3.70M | 1 | — | — | Detail |
Mar 10, 2015 | Seed | €15K | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Innovation Council | Yes | Grant |
ReumaNederland | — | Series A |
Startupbootcamp Smart Materials | — | Seed |